Who Gets the Money, Who Does the Work
Biotech company Imperagen announced on Thursday a £5 million ($6.7 million) seed round led by PXN Ventures, with participation from IQ Capital and Northern Gritstone, as investors poured more capital into a startup trying to remake enzyme engineering through quantum physics-based simulation, AI models and robots. The company was founded in 2021 by Manchester Institute of Biotechnology scientists Dr. Andrew Currin, Dr. Tim Eyes and Dr. Andy Almond and spun out of the university, another reminder that the machinery of research, capital and commercialization tends to move in the same direction: upward.
Imperagen says it wants to make enzyme engineering faster, more efficient and less costly than the slower, more physical, trial-and-error process used now. In practice, that means replacing lab-heavy mutation work with a computer-driven system that predicts enzyme behavior using advanced quantum physics modeling, then feeding that information into custom AI models trained on the enzyme problems the company wants to explore. The company says the simulation can explore millions of mutations.
Automation as the New Middleman
To keep its AI models supplied with data, Imperagen uses robots and automation to generate experimental data, which is then fed back into the model in a process called closed-loop simulation. The company presents this as a way to improve enzyme engineering, but the structure is clear enough: machines generate the data, models digest it, and investors bankroll the whole operation while the people at the bottom of the industrial chain wait for whatever products emerge.
Enzymes matter across many industries, especially pharmaceuticals, where they are essential to drug development. Startups like Imperagen are hoping to speed up enzyme engineering because it can have a domino effect, making drug discovery faster and more efficient. Enzymes are also used in food, biofuels and agriculture. Experts in sustainability are also looking to enzymes and the AI technologies surrounding them to make industrial production and manufacturing more sustainable. Others in this space include Biomatter, Cradle Bio and Absci.
On Thursday, Imperagen also announced that Guy Levy-Yurista will assume the role of CEO. He said that right now, the process of enzyme engineering is falling short, where even many new AI-powered technologies can pass trial and error but fail when put into practice on an industrial scale. That gap between the demo and the factory floor is where the promises of innovation often run into the hard edges of production, and where workers, researchers and end users are left to absorb the consequences.
The Pitch to Capital
Imperagen hopes its tech will make enzyme development “faster, more reliable, and more commercially accessible, helping companies bring better bio-based products to market without the long timelines and uncertainty that have traditionally held the field back,” Levy-Yurista told TechCrunch. His background is in AI, life sciences and enterprise technology. Though the founders will remain at the company, Levy-Yurista was brought in to help build out its new technologies, including a vertical AI infrastructure for biocatalysis, while scaling the startup’s AI strategy, commercial models and industrial partnerships.
The company has raised £8.5 million ($11.42 million) in funding to date, and the fresh capital will be used to hire more AI specialists, put toward research and development, expand its experimental lab capabilities and build a go-to-market function within the next two years. In other words, the money is not just for science; it is for staffing, scaling and selling.
Levy-Yurista said, “Ultimately, Imperagen hopes wider use of engineered enzymes will help industries reliably produce products that are cleaner, safer and better for people and the planet, while also making commercial sense for the companies that adopt them.” The sentence does what startup language always does: it wraps industrial ambition, market logic and planetary virtue into one neat package, then asks everyone else to call it progress.